Comment on: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.
作者信息
Simpson David C
机构信息
Virginia Commonwealth University, Richmond, VA, USA.
出版信息
Rev Bras Hematol Hemoter. 2013;35(2):83-4. doi: 10.5581/1516-8484.20130024.
Abstract
摘要
相似文献
1
Comment on: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.
Rev Bras Hematol Hemoter. 2013;35(2):83-4. doi: 10.5581/1516-8484.20130024.
2
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.
Rev Bras Hematol Hemoter. 2013;35(2):103-8. doi: 10.5581/1516-8484.20130030.
3
Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
Haematologica. 2010 Aug;95(8):1325-33. doi: 10.3324/haematol.2009.020636. Epub 2010 May 11.
4
Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
Haematologica. 2010 Jul;95(7):1211-5. doi: 10.3324/haematol.2009.015180. Epub 2010 Apr 21.
5
Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Haematologica. 2011 Feb;96(2):204-12. doi: 10.3324/haematol.2010.029082. Epub 2010 Nov 11.
6
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.
7
Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate.
J Cosmet Laser Ther. 2019;21(4):243-244. doi: 10.1080/14764172.2018.1525745. Epub 2018 Oct 4.
8
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Cancer Rep (Hoboken). 2018 Aug;1(2):e1111. doi: 10.1002/cnr2.1111. Epub 2018 Jul 27.
9
10
Spotlight on imatinib mesylate in chronic myeloid leukemia.
BioDrugs. 2004;18(3):207-10. doi: 10.2165/00063030-200418030-00009.
本文引用的文献
1
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.
Rev Bras Hematol Hemoter. 2013;35(2):103-8. doi: 10.5581/1516-8484.20130030.
2
The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Ther Drug Monit. 2012 Feb;34(1):85-97. doi: 10.1097/FTD.0b013e31823cdec9.
3
Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44. doi: 10.1016/s1570-0232(03)00206-x.
4
Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.
J Pharm Biomed Anal. 2002 Jun 15;28(6):1183-94. doi: 10.1016/s0731-7085(02)00080-8.
5
High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):325-40. doi: 10.1016/s1570-0232(01)00611-0.
6
The development of a staggered parallel separation liquid chromatography/tandem mass spectrometry system with on-line extraction for high-throughout screening of drug candidates in biological fluids.
Rapid Commun Mass Spectrom. 2001;15(2):73-81. doi: 10.1002/1097-0231(20010130)15:2<73::AID-RCM193>3.0.CO;2-Q.
Zotero 插件